New Clinical Trial being conducted for those that have Retinitis Pigmentosa. They are hoping that the partnership with Pixium Vision will lead to new solutions for those that have macular degeneration.

Pixium Vision Receives Clinical Trial Approval from Spanish Ministry of Health for 150 Electrode Iris®II Bionic Vision System

“Compensation for Blindness with the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy (IRIS 2)”
Pixium Vision (Paris:PIX) (FR0011950641 – PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced today that it has received approval from the Spanish Ministry of Health for clinical trial with the IRIS®II bionic vision system for patients who have lost sight due to Retinitis Pigmentosa (RP). The IRIS®II system features include a mini bio-inspired camera and a 150-electrode epi-retinal implant with an explantable design.
Barcelona’s Institute of Ocular Microsurgery IMO (Spain) joins the expanding network of centres of excellence in Europe1 involved in the clinical trial with IRIS®II. The Institute of Ocular Microsurgery is a world renowned ophthalmology center dedicated to the treatment of ocular diseases and the correction of vision. Patients in Spain will have the opportunity to participate in this European clinical trial.
Prof. Borja Corcostegui, Founder and Medical Director of the Institute of Ocular Microsurgery, IMO, a vitroretinal surgeon and the trial’s principal investigator in Spain said: “We are delighted to participate in the clinical trial with IRIS®II and become the first site in Spain. Patients blind from outer retinal degeneration in Spain can consider participation in assessing the innovative bionic vision system designed to regain a form of visual perception. Participation in clinical trials with innovative treatment options is essential for ophthalmology reference centres such as IMO. The partnership with Pixium Vision to develop solutions for retinal dystrophies, such as RP and, in the near future, Age-related Macular Degeneration (AMD), is consistent with our continuous commitment to offer cutting-edge treatment options to our patients.”…
Read more: 
Source: Business Wire